Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc., No. 24-2009 (Fed. Cir. Jan. 29, 2025)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Appellant Formycon AG appeals a preliminary injunc- tion that bars it —in the absence of a license from Regen- eron Pharmaceuticals, Inc. to Regeneron’s U.S. Patent No. 11,084,865–from marketing its biologic product ap- proved by the Food and Drug Administration (FDA) as a biosimilar to Regeneron’s FDA-approved aflibercept bio- logic product, EYLEA®. The district court’s June 21, 2024 confidential opinion granting preliminary-injunctive relief is at J.A. 1–203, and the public version is available at In re Aflibercept Patent Litigation, No.